iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...
Chemify Hires Biopharma Veteran Dr. Alastair Leighton as Chief Operating Officer
Previously at MeiraGTx, GSK and Novartis, Dr. Leighton will help Chemify scale the company’s operational capacity to meet ...
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...
devdiscourse58m
Neuberg Diagnostics Secures Landmark Investment from Kotak Alt
Neuberg Diagnostics, a diagnostics chain headquartered in India, raised Rs 940 crore from Kotak Alternate Asset Managers Ltd.
money.rediff58m
Neuberg Diagnostics Secures Rs 940 Cr Funding for Expansion
Neuberg Diagnostics, a Chennai-based diagnostics chain, has secured Rs 940 crore from Kotak Alt, becoming the largest ever ...
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 ...
Herpes Zoster (Shingles) Global Clinical Trials Review 2024: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type And End-Point Status
( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Herpes Zoster (Shingles) - Global Clinical Trials Review, 2024" clinical trials has been added to ...
ENDPOINTS NEWS56m
An­oth­er biotech scoops up as­set from Chi­na-based Keymed and nabs $180M
Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...